Boulder BioScience Leadership
Michael A. Zeligs, M.D.
Dr. Zeligs is the Co-Founder and CEO of Boulder BioScience, LLC. Dr. Zeligs is a physician and fellowship trained immunologist. His clinical career in anesthesiology included hospital experience treating acute brain injury and care of patients undergoing endovascular therapy for arterial thrombosis. As an inventor and clinical investigator, Dr. Zeligs initiated and contributed to the development of the current API. This has included use of the API in IND supported clinical trials. Dr. Zeligs’ expertise in molecular immunology and cancer-related cell signaling provides a unique background for investigation of how innate immune system activation drives sterile inflammation and the acute brain injury associated with ischemic stroke.
Elizabeth T Zeligs, MBA
Elizabeth T Zeligs is the Co-Founder and COO of Boulder BioScience, LLC. Ms. Zeligs has worked in the health care industry as an entrepreneur for over 25 years with a focus in business development, international licensing, regulatory affairs, and product development. Ms Zeligs holds a MBA from the University of Denver with an emphasis in Finance.
Irwin C. Jacobs, Ph.D.
Beginning with a doctorate in Organic Chemistry, Dr. Jacobs has served the pharmaceutical industry as a formulation scientist contributing controlled release, specialized drug delivery, and bioavailability enhancement for oral, transdermal, and parenteral dosage forms. Dr. Jacobs is co-inventor of the patented Self-Micro-Emulsifying Drug Delivery (SMEDD) technology utilized for Boulder Bioscience’s lead API and candidate drug products. Dr. Jacobs also contributes expertise to Boulder BioScience as a process and quality engineer with experience in scale-up of GMP production and launch of commercial drug products.